Fig. 3.
CDDO-Im pretreatment attenuates LPS shock induced expression of cytokines and chemokines by up-regulating antioxidative genes specifically in the lungs of nrf2 +/+, but not nrf2 −/− mice A) mRNA levels of Gclc, Gclm, and Gpx2 in the lungs of nrf2 +/+ and nrf2 −/− mice after treatment with CDDO-Im. Mice were treated with 3 doses of CDDO-Im (3 μmol/kg bodyweight) 24 h apart by intraperitoneal injection. Lungs were isolated 6 h after the last dose of CDDO-Im. The fold change was calculated using the formula described in methods. Data presented is mean fold change ± SD (n=3). B) LPS induced mRNA expression of cytokines (Tnf-α and Il-6) and chemokines (Mcp1 and Mip2) in the lung of nrf2 +/+ and nrf2 −/− mice pretreated with 3 doses of CDDO-Im. Mice were treated with 3 doses of CDDO-Im (3 μmol/kg bodyweight) 24 h apart by intraperitoneal injection. A lethal dose of LPS (50 mg/kg bodyweight) was administered peritoneally 6 h after the last dose of CDDO-Im. Lungs were isolated for measuring cytokine expression 1 h after LPS treatment. Data represented are mean fold change ± SD (n=3). * Differs from vehicle control of the same genotype; †, differs from LPS treated of the same genotype (P<0.05).